- Home
- NJR vs ADMA Comparison
NJR vs ADMA Comparison
Compare NJR & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NJR
- ADMA
- Stock Information
- Founded
- NJR 1922
- ADMA 2004
- Country
- NJR United States
- ADMA United States
- Employees
- NJR N/A
- ADMA N/A
- Industry
- NJR Oil/Gas Transmission
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NJR Utilities
- ADMA Health Care
- Exchange
- NJR Nasdaq
- ADMA Nasdaq
- Market Cap
- NJR 4.6B
- ADMA 5.1B
- IPO Year
- NJR N/A
- ADMA N/A
- Fundamental
- Price
- NJR $46.06
- ADMA $15.69
- Analyst Decision
- NJR Hold
- ADMA Strong Buy
- Analyst Count
- NJR 6
- ADMA 3
- Target Price
- NJR $51.50
- ADMA $27.67
- AVG Volume (30 Days)
- NJR 537.9K
- ADMA 2.9M
- Earning Date
- NJR 08-04-2025
- ADMA 11-06-2025
- Dividend Yield
- NJR 3.90%
- ADMA N/A
- EPS Growth
- NJR 72.02
- ADMA 469.09
- EPS
- NJR 4.10
- ADMA 0.85
- Revenue
- NJR $2,096,114,000.00
- ADMA $474,174,000.00
- Revenue This Year
- NJR $9.27
- ADMA $21.08
- Revenue Next Year
- NJR $2.24
- ADMA $25.98
- P/E Ratio
- NJR $11.26
- ADMA $18.53
- Revenue Growth
- NJR 21.02
- ADMA 43.58
- 52 Week Low
- NJR $43.80
- ADMA $13.50
- 52 Week High
- NJR $51.95
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- NJR 42.50
- ADMA 36.86
- Support Level
- NJR $46.09
- ADMA $15.14
- Resistance Level
- NJR $47.57
- ADMA $17.17
- Average True Range (ATR)
- NJR 0.67
- ADMA 0.55
- MACD
- NJR -0.09
- ADMA -0.12
- Stochastic Oscillator
- NJR 0.98
- ADMA 22.59
About NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.